High-throughput, next-generation sequencing (NGS) offers a unique opportunity for in-depth characterization of adaptive immune receptor repertoires. Nevertheless, limitations and pitfalls exist in every step of both the experimental and the analytical procedure, leading to discrepancies in the literature and incomprehensive and/or altogether misleading results. Thus, standardization of protocols in NGS immunogenetics is urgently needed.
Here, we describe the experimental protocol that we developed for T-cell receptor beta chain (TRB) gene repertoire analysis in chronic lymphocytic leukemia, aiming to provide a reproducible and biologically meaningful output. Although optimized for TRBV-TRBD-TRBJ gene rearrangements, this protocol may be customized for other adaptive immune receptor sequences, as well.
TR CLL Next-generation sequencing
This is a preview of subscription content, log in to check access.
Springer Nature is developing a new tool to find and evaluate Protocols. Learn more
Supported in part by H2020 “AEGLE, An analytics framework for integrated and personalized healthcare services in Europe”, by the EU; “MEDGENET, Medical Genomics and Epigenomics Network” (No.692298) by the EU.
Van Krieken JH, Langerak AW, Macintyre EA et al (2007) Improved reliability of lymphoma diagnostics via PCR-based clonality testing: report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia 21:201–206CrossRefGoogle Scholar
Damle RN, Wasil T, Fais F et al (1999) Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94:1840–1847PubMedGoogle Scholar
Hamblin TJ, Davis Z, Gardiner A et al (1999) Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94:1848–1354PubMedGoogle Scholar
Willemse MJ, Seriu T, Hettinger K et al (2002) Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL. Blood 99:4386–4393CrossRefGoogle Scholar
Vardi A, Agathangelidis A, Stalika E et al (2016) Antigen selection shapes the T-cell repertoire in chronic lymphocytic leukemia. Clin Cancer Res 22:167–174CrossRefGoogle Scholar
Boyd SD, Marshall EL, Merker JD et al (2009) Measurement and clinical monitoring of human lymphocyte clonality by massively parallel VDJ pyrosequencing. Sci Transl Med 1:12–23CrossRefGoogle Scholar
Wu YC, Kipling D, Leong HS et al (2010) High-throughput immunoglobulin repertoire analysis distinguishes between human IgM memory and switched memory B-cell populations. Blood 116:1070–1078CrossRefGoogle Scholar
Logan AC, Gao H, Wang C et al (2011) High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment. Proc Natl Acad Sci U S A 108:21194–21199CrossRefGoogle Scholar
Freeman JD, Warren RL, Webb JR et al (2009) Profiling the T-cell receptor beta-chain repertoire by massively parallel sequencing. Genome Res 19:1817–1824CrossRefGoogle Scholar
Robins HS, Srivastava SK, Campregher PV et al (2010) Overlap and effective size of the human CD8+ T cell receptor repertoire. Sci Transl Med 2:47–64CrossRefGoogle Scholar
Wang C, Sanders CM, Yang Q et al (2010) High-throughput sequencing reveals a complex pattern of dynamic interrelationships among human T cell subsets. Proc Natl Acad Sci U S A 107:1518–1523CrossRefGoogle Scholar
Li S, Lefranc MP, Miles JJ et al (2013) IMGT/HighV QUEST paradigm for T cell receptor IMGT clonotype diversity and next generation repertoire immunoprofiling. Nat Commun 4:2333CrossRefGoogle Scholar
Vardi A, Vlachonikola E, Karypidou M et al (2017) Restrictions in the T-cell repertoire of chronic lymphocytic leukemia: high-throughput immunoprofiling supports selection by shared antigenic elements. Leukemia 31:1555–1561CrossRefGoogle Scholar
van Dongen JJM, Langerak AW, Bruggemann M et al (2003) Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17:2257–2317CrossRefGoogle Scholar